Nevelix Pharma Ka Dhamaka! Revenue **811%** Bhaga, Profit **579%** Upar! Pharma Shift Ka Asar?

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorRiya Kapoor|Published at:
Nevelix Pharma Ka Dhamaka! Revenue **811%** Bhaga, Profit **579%** Upar! Pharma Shift Ka Asar?
Overview

Arre bhaiyo aur behno, Nevelix Pharma (pehle Trimurti Limited) ne Q3 FY26 mein toh dhamaka kar diya! Company ka revenue **811.47%** saal dar saal badh kar **₹4,840.25 Cr** ho gaya hai, aur net profit bhi **579.72%** upar **₹100.44 Cr** par pahunch gaya hai. Ye sab pharma business mein shift hone ke baad hua hai.

📈 Kya Chal Raha Hai Nevelix Pharma Mein?

Nevelix Pharmaceuticals Limited, jiska pehle naam Trimurti Limited tha, ne Q3 FY26 (December tak) mein record todh kamai ki hai. Pharma sector mein strategic shift ke baad, company ke numbers dekh kar sab chaunk gaye hain.

Aise Ude Numbers:
Company ki Income from Operations Q3 FY26 mein 811.47% saal-dar-saal badhi hai, jo ki ₹4,840.25 Cr tak pahunch gayi hai. Pichle saal isi quarter mein yeh sirf ₹529.98 Cr thi. Agar pichle quarter (Q2 FY26) se compare karein, toh 33.11% ka accha growth dikh raha hai.

Profit toh aur bhi tez bhaga! Net Profit 579.72% YoY badh kar ₹100.44 Cr ho gaya, jo Q3 FY25 mein sirf ₹14.79 Cr tha. Quarter-on-quarter bhi 88.44% ka zabardast jump aaya hai.

Earnings Per Share (EPS) bhi peeche nahi raha, 286.67% YoY badh kar ₹0.58 ho gaya.

Par Yeh Equity Ka Kya Scene Hai?
Ek baat jo dhyan dene wali hai woh yeh hai ki company ka Paid-up Equity Capital 72.99% YoY badh kar ₹1721.50 Cr ho gaya hai (pichle saal yeh ₹995.00 Cr tha). Itna bada equity dilution investors ke liye sochne wali baat hai. Yeh dekha jayega ki iska shareholder value par kya asar padta hai aur yeh paisa kahan lagaya ja raha hai.

Aage Kya? (Management Says?)
Company ne filhaal EBITDA ya margins ke baare mein koi detail nahi di hai. Na hi management ne future outlook ya analyst expectations par koi update diya hai. Toh aage kya hone wala hai, iska precise idea abhi nahi mil raha hai.

Risk Factor:
Sabse bada sawal yeh hai ki yeh hyper-growth kitni sustainable hai aur badhe hue equity capital ka company kaise istemal karti hai. Ab company ka focus pharma ingredients (Bulk Drugs) banane aur trade karne par hai. Investors ko aane wale results aur is fund utilization par nazar rakhni hogi.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.